GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » Short Interest

Alar Pharmaceuticals (ROCO:6785) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Alar Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Alar Pharmaceuticals's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alar Pharmaceuticals's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Alar Pharmaceuticals's Short Interest falls into.


;
;

Alar Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » Short Interest
Comparable Companies
TPE:4119 TPE:4746 ROCO:1799 ROCO:4166 ROCO:6576 TPE:1720 ROCO:6932 ROCO:6620 ROCO:4120 ROCO:4747 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
No. 32, Keya Road, 5th Floor, Daya District, Taichung, TWN, 407
Website
https://www.alarpharm.com
Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs.

Alar Pharmaceuticals Headlines

No Headlines